Skip to main content

Select Drug Profiles

Perspectives, Business
The Business Case for Social Determinants
David B. Nash, MD, MBA
Read More
Original Research, Practice Management
Outcomes-Based Contracting for Disease-Modifying Therapies in Multiple Sclerosis: Necessary Conditions for Paradigm Adoption
Cori Gray, PharmD; James T. Kenney, RPh, MBA
Stakeholder Perspective
Outcomes-Based Contracts Gaining Traction: Innovative Therapies Will Require Innovative Payment Methods
Gary Branning, MBA
Read More
Pancreatic Cancer, Oncology
A Review of Recent Real-World Evidence Data in Metastatic Pancreatic Cancer
Read More
In the News, Pediatric Cancer, Oncology
FDA Will Require Early Assessment of New Targeted Agents That May Be Used in Pediatric Cancers
Read More
FDA Approvals, In the News
Regenerative Medicine Advanced Therapy Designation Granted to ADP-A2M4 for Synovial Sarcoma
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory CLL: 42-Month Follow-Up of a Phase 2 Study
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
Bendamustine-Rituximab versus Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
Three-Year Update of the Phase 2 ABT-199 (Venetoclax) and Ibrutinib in Mantle-Cell Lymphoma (AIM) Study
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
Lisocabtagene Maraleucel, a CD19-Directed CAR T-Cell Product, in High-Risk Patients with R/R CLL/SLL, Including Those Previously Treated with Ibrutinib
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
Third Interim Analysis from the Phase 2 Vision HO141 Trial of Venetoclax + Ibrutinib for Patients with R/R CLL: 15-Month Safety, Response, and MRD Evaluation
Read More
Page 42 of 244
Results 411 - 420 of 2438